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Objective: Early life seizures (ELS) are often associated with cognitive and psychiatric
comorbidities that are detrimental to quality of life. In a rat model of ELS, we explored
long-term cognitive outcomes in adult rats. Using ACTH, an endogeneous HPA-axis
hormone given to children with severe epilepsy, we sought to prevent cognitive deficits.
Through comparisons with dexamethasone, we sought to dissociate the corticosteroid
effects of ACTH from other potential mechanisms of action.
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results: Although rats with a history of ELS were able to acquire a conditioned fear
learning paradigm and controls, these rats had significant deficits in their ability to
extinguish fearful memories. ACTH treatment did not alter any seizure parameters but
nevertheless was able to significantly improve this fear extinction, while dexamethasone
treatment during the same period did not. This ACTH effect was specific for fear extinction deficits and not for spatial learning deficits in a water maze. Additionally, ACTH did
not alter seizure latency or duration suggesting that cognitive and seizure outcomes
may be dissociable. Expression levels of melanocortin receptors, which bind ACTH,
were found to be significantly lower in animals that had experienced ELS than in control
animals, potentially implicating central melanocortin receptor dysregulation in the effects
of ELS, and suggesting a mechanism of action for ACTH.
interpretation: Taken together, these data suggest that early treatment with ACTH can
have significant long-term consequences for cognition in animals with a history of ELS
independently of seizure cessation and may act in part through a CNS melanocortin
receptor pathway.
Keywords: epilepsy, cognition, development, prefrontal cortex, melanocortins, ACTH

INTRODUCTION
Psychiatric comorbidities and cognitive deficits are common in pediatric epilepsy. Children with
epilepsy are at increased risk for depression, obsessive–compulsive disorder, anxiety, ADHD, autism,
significant difficulty with learning and memory, and other disorders that indicated frontal lobe
dysfunction (1–3). These comorbidities severely impact quality of life, often more than the seizures
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themselves (4, 5). Understanding the nature of these deficits and
finding effective treatment strategies is paramount.
We have previously shown that early life seizures (ELS) are
associated with cognitive deficits. These deficits are often explored
in the realm of hippocampal cognition (6, 7). More recently, we
have also shown deficits in prefrontal cognition (8), which mirror
deficits seen in children with epilepsy. Using both hippocampaland prefrontal-dependent cognitive tasks [a water maze and a
fear learning and extinction task that is associated with anxiety
phenotypes in humans and animal models (9), respectively], we
sought to understand the long-term effects of early treatment
with ACTH and the corticosteroid dexamethasone on these
aspects of cognition.
ACTH is used clinically for the treatment of infantile spasms.
It reduces seizure frequency and may also have a positive impact
of cognitive outcomes (10–14). This raises the possibility that
ACTH could also be beneficial in other epilepsies associated with
cognitive impairments. We have recently shown that ACTH is
effective in ameliorating attention deficits associated with early
life epileptiform activity and no seizures (15), but it remains
uncertain whether ACTH could modify cognitive outcomes in
the context of overt seizure activity that are not infantile spasms.
Using an ELS model instead of an infantile spasms model allows
us to explore the generalizability of ACTH treatment for other
forms of pediatric epilepsy. We hypothesized that animals with
a history of ELS would have significant deficits in fear conditioning and spatial cognition, and that ACTH administration
during the time of the seizures would prevent these deficits.
Dexamethasone is also used to treat some severe epilepsies in
children (16). Dexamethasone and ACTH are often considered
together as hormonal therapies given that a possible mechanism
of action of ACTH is via stimulation of melanocortin 2 receptors in the adrenal with consequent release of corticosterone.
However, if ACTH and dexamethasone are not similar in their
effect on cognition associated with epilepsy, then it is possible
that ACTH has mechanisms of action beyond stimulation of the
adrenal.
MC2R is found solely in adrenal cortex, but all of the members
of the melanocortin family of receptors bind ACTH with varying
degrees of specificity. Two of these receptors, MC3R and MC4R,
are expressed in the CNS, and therefore ACTH likely has direct
CNS action in addition to its action on the adrenal. Recently,
MC4R agonists have been used in animal models of Alzheimer’s
disease and stroke as neuroprotective compounds that can also
improve cognitive and behavioral outcomes (17–20). Although
MC3R and MC4R agonism has been a suggested potential
mechanism of action for ACTH in the treatment of seizures in
infantile spasms (21), the role of the melanocortin system in
cognitive impairment after ELS has yet to be explored. As such,
the final aim of this study was to quantify expression of MCRs
in the PFC and the hippocampus after ELS in order to begin to
understand whether or not there is dysregulation of this receptor
signaling pathway in our model.
The results show that ELS impairs PFC- and hippocampaldependent cognition. Early administration of ACTH, but not
dexamethasone, can prevent PFC-dependent cognitive impairment, suggesting dysregulation of central MCRs after ELS.
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Further supporting this hypothesis, MCRs are significantly
downregulated in the PFC acutely after ELS. Importantly, this
prevention occurs in the context of unchanged seizure outcomes.

MATERIALS AND METHODS
Animals

All experiments were performed in accordance with the guidelines set down by the National Institutes of Health and the Geisel
School of Medicine at Dartmouth for the humane treatment of
animals. The animal protocol was approved by the Institutional
Animal Care and Use Committee of Dartmouth College and the
Institutional Animal Care and Use Committee of the University
of Vermont.

Early Life Seizure Model

Sprague-Dawley rats were subjected to a total of 62–65 flurothylinduced seizures from postnatal day (p) 7 to p16. ELS rats and
littermate controls were separated into three groups; vehicle
treated, ACTH treated, and dexamethasone treated (N = 12
ACTH + gelatin vehicle, N = 14 dexamethasone + saline
vehicle). Each rat received six to seven seizures per day and
was allowed to recover for 1 h between seizures. Rat pups were
placed into a sealed plastic container where 0.1 mL of flurothyl,
an inhaled convulsive agent, was slowly dripped onto a small
piece of filter paper within the chamber. Pups were observed
carefully, and the chamber was unsealed and allowed to ventilate
once animals showed signs of tonic forelimb and hindlimb
extension. Littermate control pups were removed from the dam
and handled at this time to control for the effect of handling- and
maternal separation-related stress.
For experiments in which the effect of ACTH and dexamethasone on seizure latency and duration was examined, latency
to seizure was observed in paired animals simultaneously to
control for any discrepancy in injection volume and/or speed.
Twenty-three rat pups (N = 9 ACTH, N = 10 vehicle, and N = 4
dexamethasone) were exposed to flurothyl in tandem (paired
randomly together in the chamber). Latency to initial tonic forelimb extension and duration of seizure was timed in each animal.
In this cohort of animals, only one seizure was administered per
day for 5 days from p6 to p10 in order to assess changes in latency
and duration over time.

Drug Administration

For the ACTH fear learning/extinction task, ELS and littermate
control animals were injected subcutaneously with 150 IU/m2
ACTH or the same dose of gelatin vehicle control, as previously
described (10). Injections were made once daily, 1 h before ELS.
For the dexamethasone fear learning/extinction task, ELS and
littermate control animals were injected subcutaneously with
0.5 mg/kg dexamethasone or the same volume of saline vehicle
control. Injections were made once daily, 1 h before ELS.
The ELS paradigm was the same for both groups of rats. A
subset of the animals was weighed at the time of behavior; adult
weights do not differ as a function of treatment (p = 0.12 for ACTH
treatment and p = 0.20 for dexamethasone treatment). Mortality
2
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in our study was low and unrelated to seizures or treatment in
the majority of animals; only two vehicle-treated ELS animals,
one ACTH-treated, and one dexamethasone-treated animal died
during the seizure period.

Brains were then post-fixed in 4% paraformaldehyde overnight
(18 h) and transferred to 30% sucrose until the point of sinking
(2–3 days). Brains were placed in optimal cutting temperature
(OCT solution) and flash-frozen at −80°C. Coronal sections
through the infralimbic cortex and dorsal hippocampus were cut
on a −25°C cryostat at 30 μm and placed into a 24-well plate
containing 1 mL wells of PBS.
Endogenous peroxidase activity was then blocked with 1 mL
3% hydrogen peroxide for 5 min, followed by three 5-min washes
in PBS. Non-specific antigen binding was blocked by 600 μL of
1% BSA, 3% normal goat serum, and 0.25% Triton X-100 in
PBS for 30 min on a rocker. The sections were then incubated
with 400 μL of either 1:400 rabbit Anti-Melanocortin Receptor
3 (extracellular) or 1:700 rabbit Anti-Melanocortin Receptor
4 (extracellular) antibodies (Alomone Labs, Jerusalem, Israel)
at 4°C overnight (18 h) on a rocker. This was followed by three
5-min washes in PBS, followed by incubation with 400 μL 1:1000
Biotinylated Goat Anti-Rabbit IgG Antibody (Vector Labs,
Burlingame, CA, USA) for 75 min at 25°C on a rocker. Five hundred microliters of ABC avidin–biotin solution (Vector Labs)
were then added to wells, and the plate was placed on a rocker
for 30 min. Sections were washed three times with PBS, before
400 μL of DAB–peroxidase substrate (Vector Labs) was added
and left for 2–4 min. Sections were washed three times in PBS,
then mounted onto charged slides, and dehydrated sequentially
in baths of 70, 95, and 100% ethanol for 5 min each. Sections
were cleared in methyl salicylate for 5 min, before coverslips were
mounted using toluene-based mounting medium, and sealed
with clear nail polish.
For cell counting, we used a microscope with Koehler illumination at 20× magnification to count cells in layers 2–3, 5, and 6
of the infralimbic cortex, and in the CA1 pyramidal cell layer of
the hippocampus. About 20× magnification was used because it
allowed for identification of individual cells and the decreased
zoom allowed for use of a larger defined counting frame. Eight
coronal sections from each brain region were taken from each
rat and stained according to the above method: four with MC3R
antibody and four with MC4R antibody. Collection for PFC
began based on visually identified corpus callosum landmarks at
coordinates +3.5 mm to +2.9 mm anterior to bregma. Collection
for hippocampal sections began based on ventricular and cornu
amonnis landmarks at coordinates −2.8 to −4.0 mm posterior to
bregma. Every third PFC section and every sixth hippocampal
section were collected and stained. We used the optical fractionator function of Stereo Investigator (MBF Bioscience, Williston,
VT, USA), with unbiased counting frames of 50 μm × 50 μm in
the PFC and 25 μm × 25 μm in the hippocampus and grid sizes
of 200 μm × 200 μm and 100 μm × 100 μm, respectively. The
optical fraction was set at 10 μm depth, centered in the middle of
the tissue section encompassed by the counting frame. The optical fraction was realigned for every new counting frame. Only
cell tops falling within the optical fraction were counted. Cells
touching the red line of the counting frame were discounted,
whereas those touching the green line were included in the
count. A total of 1210 control and 1238 ELS cells were counted
in CA1 over an average volume of 1,990,302.6 ± 164,005.6 μm3
in controls and 1,773,171.4 ± 101,309.4 μm3 in ELS animals;

Water Maze

Animals were allowed to acclimate to the water maze room for
1 h before any testing began. Water maze was conducted in a large
(2 m in diameter by 50 cm in height) tub filled with opaque water
maintained at approximately 26°C. The room housing the water
maze contained two distal cues placed on a black cloth covering
the walls, approximately 50 cm away from the edge of the water
maze. Indirect lighting was provided near the base of the water
maze. On day 1, animals were allowed to habituate to the water and
swim freely for 1 min without any platform present. A submerged
platform was then introduced into the tub and testing began. Rats
were placed tail-first into the water from four different starting
locations selected randomly. Latency to find the platform was
timed for four trials per day over the course of 4 days.

Fear Learning Acquisition and Analysis

An operant box (Med Associates Inc., St. Albans, VT, USA)
enclosed in a dimly lit, sound-attenuating chamber with a
metal-bar floor was used for fear conditioning experiments. Rats
were trained in a standard fear conditioning task. On day 1, all
animals were habituated to the room and then the operant box
where fear conditioning was to take place. On days 2 and 3, fear
learning commenced. Each trial consisted of two 10 s presentations of a tone followed immediately by a 1-s, 0.75 mA footshock
(inter-trial interval 64 s). There were three trials per session, one
session per day. Behavior was recorded with a video camera and
analyzed offline. For analysis, the instantaneous state of the rat
was scored at 2, 10, 18, 26, 34, 42, 50, and 58 s after the second
tone; 1 for moving and 0 for freezing (immobility with the exception of breathing). Freezing or moving scores were also collected
during a 3-min pre-tone baseline in the operant chamber where
the testing took place prior to administration of any tone or
footshock.

Fear Extinction

Fear extinction trials began 24 h after the second session of fear
learning. For extinction, rats were placed in the same operant
box, and the conditioned stimulus tone was played 30 times for
10 s. Behavior was recorded with a video camera and analyzed
offline. Moving behavior at 2, 6, 8, and 10 s after the beginning of
the tone was scored and averaged to give one value per tone; 1 for
moving and 0 for freezing at each of those time points. Freezing
was defined as complete immobility with rigid body posture.

Immunohistochemistry and Cell Counting

Early life seizures animals (N = 8 control, N = 9 ELS) were euthanized at p19, 36 h after the ELS paradigm had ended. Animals
were deeply anesthetized with isoflurane (4–5% in oxygen) until
breathing slowed, and rats were unresponsive to a tail and paw
pinch. Animals were then perfused transcardially with approximately 20 mL of PBS followed by 30 mL of 4% paraformaldehyde.
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in control (N = 4) or ELS animals (N = 3) (Figure 1A) (main
effect of treatment; p = 0.575). Overall, all groups of animals
learned the task in one session (main effect of tone; p < 0.001).
Twenty-four hours after the end of fear learning trials, fear
extinction trials began. ELS rats had a significant deficit in
fear extinction and exhibited freezing behavior significantly
more frequently throughout the whole session than controls
(Figure 1B; p < 0.0001). Although the vehicle-treated control
animals exhibited clear extinction over the session, the vehicletreated ELS group had a moving score of 0.05 ± 0.02 by the
30th tone, where a value of 1 would indicate moving during
all measured time points after the tone and a value of 0 would
indicate freezing during all measured time points after the tone.
This demonstrates that ELS animals were unable to extinguish
even at the end of the extinction session (Figure 1B). In
addition, moving scores of vehicle-treated ELS animals were
significantly different to vehicle-treated controls at the 30th
tone (p < 0.001).

a total of 16,833 control and 8193 ELS cells were counted in
mPFC over an average volume of 5,062,576.6 ± 188,003.2 μm3 in
controls and 3,605,728.1 ± 133,541.2 μm3 in ELS animals. Cells
were counted blindly to reduce subjective bias. To eliminate bias
due to area and thickness of tissue, cell counts were divided by
volume of the section to obtain the more representative measure
of cell density.

Statistics

All fear learning and extinction data and cell staining counts
were modeled using generalized estimating equations (GEE) in
SPSS v22 (IBM corporation, Chicago, IL, USA) in order to ensure
that the most appropriate data distribution was assumed and in
order to deal with repeated measures. For the behavioral data,
the dependent variable was moving score. For the immunohistochemistry (IHC) data, the dependent variable was number
of cells stained per volume of tissue. Group was modeled as a
factor, with tone number as a covariate in the behavioral data.
Fear extinction moving scores were best modeled as a linear scale
response, whereas fear learning scores were modeled assuming a
binomial distribution. In order to understand how the learning
differed between the groups, all data were examined as group
by tone effects and therefore describe mean differences between
groups in the rate of learning as a function of tone. For extinction
data where differences in the 30th (final) tone were reported, a
one-way ANOVA using a Tukey post hoc test was used. Seizure
duration and latency were also modeled using a GEE assuming a
gamma distribution. Treatment (ACTH or vehicle) was used as a
factor with day as a covariate.
Morris water maze data were analyzed using a multivariable Cox regression time-to-event approach in STATA (SEv13,
StataCorp, TX, USA), as previously described (22, 23). Traditional
analyses used to analyze water maze data have been questioned
and time-to-event analyses are considered to be more appropriate. Specifically, Jahn-Eimermacher et al. argue against the use
of ANOVAs, etc., in lieu of survival analysis for water maze and
other behavioral data (24). Frailty Cox models were applied to
deal with repeated measures over day. In addition to being the
most appropriate way to analyze water maze data, this approach
also allowed us to investigate the interaction between ELS and
ACTH treatment while accounting for within-animal correlations. The time-to-event was the latency (in seconds) to find the
platform.
All values are reported as estimated marginal means ± SEM.

ACTH Improves Fear Extinction
in ELS Animals

The rate of fear extinction is not altered with ACTH administration in control animals (p = 0.45; group by tone, vehicle-treated
controls vs. ACTH-treated controls). However, importantly,
the rate of extinction in ELS animals treated with ACTH is also
indistinguishable from vehicle-treated controls (p = 0.15; group
by tone, vehicle-treated controls vs. ACTH-treated ELS, see
Figure 1B). This suggests that ACTH restores fear extinction in
animals with a history of ELS. This is also reflected by comparison
of moving scores at the end of the fear extinction session. At the
30th tone, moving scores of ACTH-treated ELS animals were
significantly higher than ELS animals (p = 0.006) and were not
significantly different from vehicle-treated controls (p = 0.1).

ACTH Does Not Ameliorate Water
Maze Deficits

We have previously reported that the ELS paradigm significantly
impairs hippocampal-dependent learning and memory. In order
to determine whether or not treatment with ACTH was effective
in ameliorating these deficits, we used a second cohort of animals that had experienced ELS with (N = 5) or without (N = 4)
ACTH treatment from p6 to p16. Overall, all animals learned to
find the platform, as seen by a significant effect of day (p < 0.001,
Figure 2A). As previously reported, animals experiencing ELS
have significant impairments during the Morris water maze
(p = 0.01) in adulthood compared to controls (N = 6 treated
with vehicle; N = 6 treated with ACTH). We found no change
in water maze performance when animals were administered
ACTH (p = 0.71) suggesting that treatment with ACTH does not
improve hippocampal-dependent spatial cognition (Figure 2B).

RESULTS
ELS Cause Significant Deficits in Fear
Extinction but Not Fear Learning

We first tested the effect of ELS on fear learning acquisition and
subsequently fear extinction, two prefrontal-dependent tasks.
No significant alterations in fear learning were noted in vehicletreated animals experiencing ELS (N = 8) compared to controls
(N = 8) (ELS effect; p = 0.427). ACTH administration in control
(N = 6) or ELS animals (N = 5) did not significantly affect fear
learning (Figure 1A) and nor did dexamethasone administration

Frontiers in Neurology | www.frontiersin.org

Dexamethasone Does Not Improve
Fear Extinction in ELS Animals

Early treatment with dexamethasone may actually worsen the rate
of extinction for control animals (p = 0.003, group by tone effect
comparing vehicle-treated to dexamethasone-treated controls),
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FIGURE 1 | Fear conditioning after ELS and treatment with dexamethasone or ACTH. Each panel represents a treatment condition, with the left panel
depicting moving scores from vehicle-treated animals, the middle panel showing ACTH-treated animals, and the right panel dexamethasone-treated animals. All
animals in all groups acquired the fear learning paradigm after three tone-shock pairings (A). However in (B), vehicle-treated ELS animals (red open circles, left
panel) had significant deficits extinguishing the fear task compared to vehicle-treated controls (blue open circles, left panel), even after 30 tones without shock
pairing. Treatment with ACTH (filled triangles, middle panel) did not alter fear extinction in control animals (blue) but significantly prevented fear extinction in animals
with a history of ELS (red). Treatment with dexamethasone (stars) did not significantly improve fear extinction in animals with a history of ELS (red), even with the
inclusion of one outlier animal representing two data points at tones 20 and 25 (shown as red Xs in the right panel).

although the groups are not significantly different by the end of
the extinction session (p = 0.07 at tone 30).
However, unlike ACTH, dexamethasone treatment in ELS
animals does not restore fear extinction to the levels of vehicletreated controls as the rate of extinction was significantly different
between the groups (p = 0.04; group by tone comparing vehicle
Frontiers in Neurology | www.frontiersin.org

control to dexamethasone-treated ELS). It is also worth noting
that one animal in this group had outlier measurements at tone 20
and tone 25 (shown as red Xs in panel 3 of Figure 1B); with these
outliers removed, this effect is even more significant (p < 0.001).
Indeed, dexamethasone treatment did not significantly improve
the rate of fear extinction compared to vehicle-treated ELS

5
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FIGURE 2 | ELS-associated deficits in water maze are not improved with ACTH. Time-to-event (survival) analysis of the latency to find the platform in a
Morris water maze task show that animals have a shorter latency to find the platform on day 4 (purple line) compared to day 1 (pink line). This indicates that, when
adjusted for group, animals on average learn over the 4-day time course of the experiment (A). We then show in (B) that animals with a history of ELS have
significant deficits in water maze (green line) over controls (blue line), seen as an increased proportion of animals having longer latencies to find the platform when
day and trial are accounted for statistically. Treatment with ACTH during the time of the seizures does not improve this deficit (yellow line). Likewise, treatment with
ACTH does not alter latency to find the platform in control animals (red line) as well.

(p = 0.39, group by tone comparing vehicle-treated ELS to
dexamethasone-treated ELS). This is also true when comparing
moving scores at the final tone (p = 0.966, group effect comparing
vehicle-treated ELS to dexamethasone-treated ELS).

after ELS, this could point to a role of MCRs in the mechanism
of action of ACTH in improving cognitive outcome. To address
this question and confirm the presence of these receptors in these
brain regions at this age, we stained and quantified cells expressing MC3R and MC4R in the infralimbic cortex of the mPFC and
CA1 of the dorsal hippocampus in control and ELS animals at
p19 (Figures 4A–F). In the infralimbic cortex, we found that the
density (cell count/10,000 μm3) of cells expressing these MCRs
was significantly lower in ELS animals than in controls across all
layers (Figures 4A,B; p = 0.019 for MC3R; p = 0.001 for MC4R).
However, the density of cells expressing MC3R or MC4R in the
pyramidal cell layer of CA1 was not significantly different between
groups (Figures 4C,D; p = 0.75 for MC3R; p = 0.33 for MC4R).

ACTH and Dexamethasone Do Not Alter
Seizure Latency or Duration

Having found that ACTH partially rescued the ability of ELS rats to
extinguish fear, we then wanted to determine the effects of ACTH
and dexamethasone administration on seizure properties in the
flurothyl model of ELS. Overall, we found a significant reduction
in latency and an increase in duration in both groups over day
(main effect of day: p = 0.004 duration of seizure; p < 0.001 latency
to seizure). There was no difference in the latency (Figure 3A)
to or duration (Figure 3B) of flurothyl-induced seizures with
administration of ACTH or dexamethasone; mean latency was
116.47 ± 11.5 s in the vehicle-treated animals compared to
106.29 ± 5.6 s in ACTH-treated animals and 119.16 ± 18.5 s in
dexamethasone-treated animals (p = 0.63 group effect; p = 0.98
group × day effect), mean duration was 80.24 ± 12.6 s in vehicletreated animals compared to 66.71 ± 4.9 s in ACTH-treated
animals and 68.52 ± 7.8 s in dexamethasone-treated animals
(p = 0.44 group effect; p = 0.27 group × day effect) (Figure 3).

DISCUSSION
Children with many different forms of epilepsy are significantly
more likely to experience cognitive deficits consistent with frontal
lobe dysfunction, including anxiety (25–28). Fear extinction is a
reliable measure of prefrontal cognition in animal models (29, 30).
Here, we show that rats with a history of ELS have significant
deficits in fear extinction and spatial learning as adults, confirming that ELS animals have both hippocampal and prefrontal
dysfunction. Additionally, we show that ACTH can prevent some
of these cognitive deficits. This is the first time that the long-term
cognitive impact of treatment with ACTH has been shown and
suggests that add-on treatment with a melanocortin agonist
during childhood seizures may lead to improvements in specific
cognitive domains during adulthood. It is worth noting that the
decision to use an ELS model instead of an infantile spasms model
allows us to understand the generalizability of ACTH treatment
for other forms of pediatric epilepsy as well.

ELS Significantly Reduce MC3R and
MC4R Expression in the PFC but
Not in CA1

As ACTH only improved the rate of fear extinction in animals with
a history of ELS and dexamethasone did not, we wanted to determine whether the melanocortin receptor system of the CNS was
altered after ELS. If central MCR system dysfunction was noted

Frontiers in Neurology | www.frontiersin.org

6

May 2016 | Volume 7 | Article 65

Massey et al.

ACTH and Cognition After ELS

context of a negative seizure improvement outcome has never
been evaluated in humans; our data presented here and the data
of Baram’s group suggest that this may warrant further study.
An unexpected finding of our research was that ACTH was
able to ameliorate cognitive deficits in PFC-dependent fear
extinction, but it was unable to do so in hippocampal-dependent
spatial learning. This difference in drug efficacy between the two
tasks suggests that following ELS there may be something fundamentally different in the way these two brain regions respond that
enables ACTH to protect one, but not the other. Quantification of
MC3R- and MC4R-expressing cells reveals a correlation that may
pose an explanation. Our results show that MC3R and MC4R are
expressed in both the infralimbic cortex and in the CA1 of hippocampus in control rats. However, following ELS, the density of
cells expressing MC3R and/or MC4R was significantly decreased
in the PFC compared to controls, but not significantly different
in the CA1 between ELS rats and controls. As ACTH binds these
receptors and was able to protect PFC cognition but not hippocampal cognition, this suggests a role for central melanocortin
signaling in this cognitive protection. We initially chose a time
point of 36 h after the induction of the last seizure in order to
assess the acute effect of the ELS insult on receptor expression.
Our results show that MCRs are present in mPFC and CA1 at p19
and are dysregulated by the ELS insult, thereby strengthening the
hypothesis that ACTH acts via a CNS MCR-mediated mechanism
to protect against injuries to prefrontal cognition. Important
future directions include characterization of the effect of ACTH
on the expression of MC3R and MC4R in rats with a history of
ELS, and whether these differences in expression between control
and ELS rats at p19 persist into later life.
ACTH, acting through MC2Rs in the adrenal cortex, leads to
systemic release of glucocorticoid steroid hormones; and although
glucocorticoid steroid hormones, such as dexamethasone, are
able to modulate the formation, consolidation, and retrieval
of fear memory acutely in adult controls (33), their long-term
effect on pediatric patients with a history of seizures is unknown.
The comparison of ACTH and dexamethasone in our study
suggests that typical glucocorticoids would not have the same
positive long-term impact on patients as ACTH, despite acute
administration of glucocorticoids enhancing extinction in adults
with phobias (34), and exogenous corticosterone administration
facilitating fear extinction in mice (35). Indeed, an unexpected
finding of the current study was the suggestion of a detrimental
effect of dexamethasone on control rats. While the mechanism
for this is unknown and not within the scope of the current study,
it does indicate that the positive impact of ACTH on cognition is
not entirely due to corticosteroid release. This also suggests that
ACTH and not prednisone, another glucocorticoid drug given to
patients that has some mineralocorticoid activity but no activity
at melanocortin receptors, may be beneficial in improving cognitive outcome. This result is not entirely unexpected, as there is
some evidence that treatment with ACTH can improve cognitive
outcomes in human patients with epilepsy. In a study done by
Kivity and colleagues, children with cryptogenic infantile spasms
normally associated with poor cognitive outcome were treated
with high-dose ACTH. The authors note that early treatment
was associated with a favorable long-term cognitive outcome

FIGURE 3 | Seizure parameters are not altered by dexamethasone
and ACTH treatments. Treatment with dexamethasone (squares) or ACTH
(triangles) does not alter latency to flurothyl seizure or latency to flurothyl
seizure over the course of 4 days compared to vehicle-treatment (circles) (A).
Likewise, treatment with dexamethasone or ACTH did not significantly alter
seizure duration (B).

Treatment with either ACTH or dexamethasone 1 h prior to
seizures did not significantly reduce seizure duration or latency
in our model; but interestingly ACTH, and not dexamethasone,
was able to prevent deficits in fear extinction in the long term.
This suggests that ACTH has an additional mechanism to its cortisol-mediated effect, which could prevent deficits in prefrontal
cognition. This also serves to challenge the notion that seizures
themselves are solely responsible for cognitive deficits – a notion
that pervades much of the literature as an unproven assumption.
If ACTH does not alter seizure parameters and seizures were the
sole cause of cognitive deficits, we would not expect ACTH to
positively impact cognition, as shown both here and in a different
seizure-related model (15), it does. To the best of our knowledge,
only one other group has data to suggest that cognitive and seizure
outcomes may be dissociable. In a model of prolonged febrile seizure, decreased T2 signal in the whole brain is neuroprotective in
terms of cognitive outcome (31), but decreased T2 signal in the
amygdala is a biomarker for the development of future temporal
lobe epilepsy (32). An improvement in cognitive outcome in the
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FIGURE 4 | Melanocortin receptor expression is downregulated in the PFC after ELS. In all layers of the mPFC, MC3 (A) and MC4 (B) receptors are
significantly downregulated (p = 0.019 for MC3Rs; p = 0.001 for MC4Rs) in ELS animals (red bars) compared to control (blue bars). No significant group by layer
effect was noted. No significant changes were noted in CA1 of the hippocampus in either MC3 (C) or MC4R (D) expression after ELS. Representative images of
MC3R and MC4R staining in PFC are shown in (E), and MC3R and MC4R staining in CA1 are shown in (F) at 20× magnification. N = 8 control, N = 9 ELS.

in all patients (10). In the UKISS study evaluating treatments
for infantile spasms, children with no identified etiology and
who received either ACTH or a corticosteroid, had significantly
higher Vineland adaptive behavior scores at follow-up than
children receiving vigabatrin (11). Interestingly, in parallel to
our current study, no clear correlation between seizure freedom
and outcome was established in the UKISS study. We show
here for the first time a potential mechanism for this improvement. Together, this research suggests that early diagnosis and
treatment of pediatric epilepsies with ACTH may be of utmost
importance to avoid some of the associated deleterious cognitive
dysfunction.
Our results provide the first investigations of a potential
mechanism underlying ACTH-related cognitive improvement
after ELS, potentially implicating central melanocortin receptors, MC3 and/or MC4R. Understanding the mechanism behind
improved cognitive outcome has the potential to elucidate novel
therapeutic targets for specifically directed add-on therapies for

cognition in epilepsy. Additionally, the effectiveness of ACTH in
improving cognitive outcome in our ELS model, instead of an
infantile spasms model, suggests potential for generalizability of
this putative novel therapeutic target beyond very severe epilepsies more broadly to pediatric epilepsy in general.
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